Synopsis:
Blue Jet Healthcare Ltd is in focus after its promoter Akshay Bansarilal sold 6.19 percent stake through OFS.
A small-cap pharmaceutical company engaged in manufacturing and selling intermediates and APIs for healthcare products, is in the spotlight after its promoter sold 6.19 percent stake through Offer for sale.
With the market capitalization of Rs. 12,354.21 crore, the shares of Blue Jet Healthcare Ltd is trading at Rs. 712.25, down by 0.66 percent from its previous day close price of Rs. 716.95. The stock has made an intraday low of Rs. 706.
What’s the News?
Akshay Bansarilal Arora, one of the promoters of Blue Jet Healthcare Limited, sold 10,734,529 equity shares, representing a 6.19 percent stake, on September 10, 2025 and September 11, 2025, through an Offer for Sale (OFS) to comply with SEBI’s minimum public shareholding (MPS) requirement. The floor price for the offer was set at Rs. 675 per share.
Also Read: Infra stock in focus after receiving ₹8 Cr order from Torrent Gas Jaipur for gas pipeline project
About the Company
Blue Jet Healthcare Limited, incorporated in 1968 and headquartered in Thane, is a pharmaceutical company engaged in manufacturing and selling intermediates and APIs for healthcare products.
Its offerings include contrast media intermediates, niche APIs, CDMO/CMO services, and end-to-end solutions from process development to commercialization of NCEs, advanced intermediates, and building blocks.
The company also develops and markets saccharin and its salts, with operations across India, Europe, the U.S., and other international markets. As of FY25, the company has a commercialized product portfolio of 51 products and a total reaction capacity of 1,177.9 KL across three manufacturing facilities.
Financial Outlook
In Q1FY26, revenue rose 4 percent QoQ to Rs. 355 crore from Rs. 340 crore in Q4FY25 and 118 percent YoY from Rs. 163 crore in Q1FY25. Operating profit came in at Rs. 121 crore, down 14 percent QoQ from Rs. 140 crore but up 175 percent YoY from Rs. 44 crore.
Net profit stood at Rs. 91 crore, declining 17 percent QoQ from Rs. 110 crore yet surging 139 percent YoY from Rs. 38 crore. EPS in Q1FY26 was Rs. 5.26, compared with Rs. 6.35 in Q4FY25 and Rs. 2.18 in Q1FY25. The results highlight strong annual growth in revenue and profitability, though sequential performance was weaker due to contraction in operating margins.
A return on equity (ROE) of about 30.2 percent, a return on capital employed (ROCE) of about 39.8 percent and debt to equity ratio at 0.02 demonstrate the company’s financial position. At the moment, the company’s P/E ratio is 34.4x slightly higher as compared to its industry P/E 33.6x.
Written by Akshay Sanghavi
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
